Figure S3 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
Year: 2026
Type: other
Abstract: KB528 treatment leads to changes in the acetylation of transcription factors and chromatin in MM cells and results in changes to the IRF4 signature similar to IRF4 knockdown.
Authors: W. Frank Lenoir, Michael R. McKeown, Giulia Giorgetti, Marek J. Kobylarz, Tamara D. Hopkins, Wayne L. Glore, Michelle G. Shum, Yaretzi Calderón, Jessica Encinas Mayoral, Luis A. Carvajal, Kameron R. Mori, Jun Li, Hua Gao, Yupeng Zheng, Zhihua Ma, Nikolaus D. Obholzer, Minyun Zhou, Benjamin W. Trotter, Christopher J. Dinsmore, Nikhil C. Munshi, Charles Y. Lin, Mariateresa Fulciniti, Peter B. Rahl
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7130616071